Navigation Links
Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease
Date:5/20/2008

ients who had relapsed during PRECiSE 2 but were treated with one additional dose of Cimzia(R) (PRECiSE 4), achieved and maintained remission at six and 12 months with maintenance dosing every 4 weeks and no dose escalation. [Abstract #T1133]

"The DDW meeting marks an exciting time to announce additional long-term data for Cimzia(R), given its recent approval by the FDA," said Olav Hellebo, Senior Vice President and President of Inflammation Operations, UCB. "UCB remains committed to providing healthcare professionals with effective therapies to improve the lives of patients suffering from this debilitating disease.

In a related analysis of PRECiSE 2 and 3, the durability of long-term maintenance of response and remission proved not to be related to the rapidity or magnitude of response or remission following induction of Cimzia(R), demonstrating that patients can go on to experience positive response and remission rates regardless of the magnitude and speed of the initial response. [Abstract #T1126]

The pooled data also shows that the PRECiSE Phase 2 and Phase 3 clinical trials showed no unexpected safety findings and no increase in the rate of common adverse events with sustained exposure to Cimzia(R). Results also demonstrate stable dosing in patients taking the medication for more than six months. [Abstract #469]

About the PRECiSE Clinical Trial Program

PRECiSE, one of the largest, most comprehensive development programs for an anti-TNF for Crohn's disease is composed of two placebo-controlled studies and two open-label safety follow-up studies. In 2007, the two former studies were published in the New England Journal of Medicine (NEJM). The studies demonstrated that patients with moderate to severe Crohn's disease achieved and sustained clinical response with Cimzia(R) for up to six months, compared to placebo. The safety and tolerability of Cimzia(R) was consistent with that expected of an anti-TNF agent. In the first follow-
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
2. Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
3. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
4. New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
5. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
6. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
7. Gene Therapy Provides Vision to People who Were Nearly Blind
8. Arpida Provides Further Comments on the Pivotal Phase III Trials
9. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
10. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
11. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  MedScope ( www.medscope.org ), ... nominated for a 2015 Connected World magazine ... Response System (mPERS), that can be used anywhere, anytime. ... partner.  In nominating MedScope, Landon ...
(Date:1/23/2015)... all-time hits leader, is the new spokesperson for the topical ... announced. "Pete,s a Hall of Famer in our ... with Myoflex," said Ducere Pharma Chief Executive Officer Chris ... across all generations. The passion and intensity that Pete brought ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: ... Phase I trial of Lixte,s lead compound, LB‑100, is being ... John S. Kovach , M.D., the founder and ... to be completed at a single site. Accrual of patients, ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... , SOUTH PLAINFIELD, N.J. , ... announced the initiation of an additional clinical trial of ataluren ... Becker muscular dystrophy (nmDBMD) who have permanently lost the ... methods for measuring functional abilities in patients who have lost ...
... , NEW YORK , Jan. 19 ... Increase Exposure to Non-Cyclical, Laggard Sectors; Maintain Exposure to US ... phase of recovery is over, markets are moving into a ... investors are paying more attention to valuations, particularly in the ...
Cached Medicine Technology:PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 2PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 3PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 4PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 5PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 6Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms 2Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms 3Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms 4
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in ... Player Health Alliance (PPHA). The PPHA's passion for others' ... including NFL greats, treated for obstructive sleep apnea (OSA) has ... the cause in the valley. The most recent plans for ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting ... . , Purchasing an accidental death and dismemberment rider ... type of rider provides benefits if the insured dies in ... lesser form of life insurance. , AD&D is not ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy ... its highest annual revenues in the past three years. Today, ... wedding dresses. , According to the sales manager of the ... for them in 2015. This point can be reflected on ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... Who: The American Society for Radiation Oncology (ASTRO) the world,s ... 10,000 members who use radiation to treat cancer and other ... ASTRO,s 53rd Annual Meeting: "Patient-focused, High-quality, Multidisciplinary Care." ... a.m. - 4:30 p.m. Note: Press room days have changed. ...
... (HealthDay News) -- Older, heavier women tend to have fewer ... study suggests. The study included 52 women who experienced ... The women,s body fat percentage, waist circumference and ... skin monitor and electronic diary were used to track their ...
... News) --,Hospitalized children who carry a dangerous type of ... still at high risk for developing full-blown infections, a ... aureus (MRSA) -- is linked to more than 18,600 ... Hopkins Children,s Center researchers examined the medical records of ...
... defibrillators, simpler may be safer, even though more complex machines ... a new study from a team that included University of ... reviewed more than 100,000 records of cardiac patients. They found ... with devices that require electrical leads to be attached to ...
... [EMBARGOED FOR AUG. 31, 2011, ARLINGTON, Va.] Immunizations, ... to protect children from life-threatening pneumonia, according to new ... the Infectious Diseases Society of America (IDSA)., The guidelines, ... pneumonia (CAP) in infants and children, place preventing bacterial ...
... , TUESDAY, Aug. 30 (HealthDay News) -- Changes in diet ... researchers say. Their findings, published online Aug. 30 in ... virus populations in the gut, how they differ from person ... "Our bodies are like coral reefs, inhabited by ...
Cached Medicine News:Health News:Being Heavier May Mean Fewer Hot Flashes for Women Over 60 2Health News:Kids Carrying MRSA Germ Prone to Serious Infection: Study 2Health News:IDSA/PIDS announce guidelines for treating pneumonia in children 2Health News:IDSA/PIDS announce guidelines for treating pneumonia in children 3Health News:IDSA/PIDS announce guidelines for treating pneumonia in children 4
... new system to help you meet the ... system's one-piece design creates a broad area ... radiographic assessment. The slotted superior and inferior ... column and are flared outward for greater ...
... With 36 joules delivered energy, the Atlas+ HF ... patient safety, programming flexibility, comfort, and quality of ... most powerful ICD offering cardiac resynchronization therapy (CRT), ... 81 gram and 40 cc physiologic-shaped can. In ...
... Intramedullary fixation has greatly ... tibial fractures. The Biomet Low ... indicated in the treatment of ... metastatic disease with pathologic or ...
... The Elite™ Premium Shoulder Instrument ... flexibility in arthroscopic and mini-open ... cuff and Bankart repair. Smith ... been designed to facilitate an ...
Medicine Products: